Chart pattern: Double Bottom (weekly)
▲ Broken out
Broke on Oct 30, 2026 · measured target $519.60 (+13%). Details →
Nov 3, 4:05 PM ET
Amgen reported third-quarter 2026 financial results, showing an 8% increase in total revenues to $10.4 billion compared to the same period in 2025. GAAP earnings per share rose 19% to $7.08, while non-GAAP earnings per share grew 14% to $6.45.
- Total revenues for the third quarter of 2026 increased 8% year-over-year to $10.4 billion.
- GAAP earnings per share rose 19% to $7.08 for the third quarter of 2026.
- Non-GAAP earnings per share increased 14% to $6.45 for the third quarter of 2026.
- Full-year 2026 total revenues are expected to be in the range of $38.9 billion to $39.7 billion.
Read the filing on SEC.gov ↗
Oct 26, 5:58 PM ET
Amgen's board appointed David W. Gibbs as a director effective October 26, 2026. He will sit on the Audit Committee and the Compensation and Management Development Committee, and the board will have 13 directors, 12 of them independent. The filing describes a board seat, not a change in management, and discloses no financial results.
- Gibbs was CEO of Yum! Brands from 2020 to September 2025 and has advised the company since October 2025.
- He also serves on the boards of Under Armour, Inc. (since 2021) and PepsiCo, Inc. (since 2026).
- Non-employee director pay includes a $115,000 annual cash retainer and a $220,000 annual equity grant, prorated for 2026.
- The board will have 13 directors, 12 of whom are independent.
Read the filing on SEC.gov ↗
Aug 4, 4:03 PM ET
Amgen reported second-quarter 2026 results on August 4, 2026, with total revenues up 10% to $10.1 billion and non-GAAP EPS up 4% to $6.29. The company also issued full-year 2026 guidance of $38.2 billion to $39.4 billion in total revenues and non-GAAP EPS of $22.30 to $23.50. Product sales were mixed: Repatha, Evenity and Tezspire grew strongly, while Prolia and Otezla declined.
- GAAP EPS rose 65% to $4.37 from $2.65, and GAAP operating income rose to $3.5 billion from $2.7 billion.
- Non-GAAP operating margin was 48.4%, down 0.5 percentage points from a year earlier.
- Free cash flow was $3.5 billion versus $1.9 billion, and the company made no share repurchases in the quarter.
- Prolia sales fell 32% to $759 million, while Repatha sales rose 37% to $953 million.
Read the filing on SEC.gov ↗
Jul 31, 4:03 PM ET
Amgen disclosed in an SEC 8-K filed July 31, 2026 that unauthorized actors accessed and exfiltrated some company data, including proprietary data and patient protected health information, from cloud environments hosted by third-party providers. The company determined on July 29, 2026 that the incident is material, but says it has not identified any impact on products, manufacturing, financial reporting systems, or its ability to meet patient needs, and does not expect a material effect on financial condition or results.
- Unauthorized activity was identified in July 2026 in data stored in third-party-hosted cloud environments.
- Company determined on July 29, 2026 that the incident is material, citing file volume and the sensitivity of the information.
- Amgen believes the incident is not reasonably likely to have a material impact on its financial condition or results of operations.
- Investigation is ongoing, and patient notifications will be made as required.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.